C M Bidwell & Associates Ltd. acquired a new position in shares of Insulet Co. (NASDAQ:PODD) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 2,730 shares of the medical instruments supplier’s stock, valued at approximately $188,000.

Several other large investors have also recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of Insulet by 2.2% during the second quarter. Vanguard Group Inc. now owns 4,655,119 shares of the medical instruments supplier’s stock worth $238,854,000 after acquiring an additional 98,272 shares during the period. Frontier Capital Management Co. LLC boosted its holdings in shares of Insulet by 42.4% during the fourth quarter. Frontier Capital Management Co. LLC now owns 2,096,131 shares of the medical instruments supplier’s stock worth $144,633,000 after acquiring an additional 624,465 shares during the period. State Street Corp boosted its holdings in shares of Insulet by 7.7% during the second quarter. State Street Corp now owns 1,189,155 shares of the medical instruments supplier’s stock worth $61,014,000 after acquiring an additional 85,280 shares during the period. Lord Abbett & CO. LLC boosted its holdings in shares of Insulet by 29.6% during the second quarter. Lord Abbett & CO. LLC now owns 838,302 shares of the medical instruments supplier’s stock worth $43,013,000 after acquiring an additional 191,217 shares during the period. Finally, Northern Trust Corp boosted its holdings in shares of Insulet by 3.2% during the second quarter. Northern Trust Corp now owns 777,986 shares of the medical instruments supplier’s stock worth $39,919,000 after acquiring an additional 24,188 shares during the period.

Shares of Insulet Co. (NASDAQ:PODD) opened at $75.84 on Monday. The company has a debt-to-equity ratio of 4.65, a current ratio of 4.88 and a quick ratio of 4.42. Insulet Co. has a 12 month low of $38.43 and a 12 month high of $78.65. The stock has a market capitalization of $4,412.98, a P/E ratio of -151.68 and a beta of 1.59.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, November 2nd. The medical instruments supplier reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.06. Insulet had a negative return on equity of 43.85% and a negative net margin of 6.66%. The firm had revenue of $121.80 million during the quarter, compared to analysts’ expectations of $114.02 million. During the same period in the prior year, the company earned ($0.05) earnings per share. The company’s quarterly revenue was up 28.4% on a year-over-year basis. research analysts predict that Insulet Co. will post -0.43 EPS for the current year.

In other Insulet news, Director James C. Mullen bought 2,500 shares of the business’s stock in a transaction on Monday, November 13th. The stock was purchased at an average cost of $67.45 per share, for a total transaction of $168,625.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.90% of the stock is owned by corporate insiders.

Several equities research analysts recently issued reports on the company. Jefferies Group boosted their price target on Insulet from $58.00 to $67.00 and gave the company a “buy” rating in a research note on Friday, November 3rd. Zacks Investment Research cut Insulet from a “buy” rating to a “hold” rating in a research note on Saturday, November 11th. Wedbush reiterated a “buy” rating and issued a $65.00 price target (up from $60.00) on shares of Insulet in a research note on Tuesday, October 10th. Barclays reiterated a “buy” rating and issued a $78.00 price target on shares of Insulet in a research note on Wednesday, December 13th. Finally, BidaskClub cut Insulet from a “buy” rating to a “hold” rating in a research note on Saturday, December 2nd. Eight equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $62.53.

ILLEGAL ACTIVITY NOTICE: This story was reported by Watch List News and is the property of of Watch List News. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.watchlistnews.com/2730-shares-in-insulet-co-podd-purchased-by-c-m-bidwell-associates-ltd/1845324.html.

About Insulet

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.